Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antipsychotic medication
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
N05AE05
|
| gptkbp:brand |
gptkb:Latuda
|
| gptkbp:CASNumber |
367514-87-2
|
| gptkbp:chemicalFormula |
C28H36N4O2S
|
| gptkbp:contraindication |
strong CYP3A4 inducers
strong CYP3A4 inhibitors |
| gptkbp:developer |
gptkb:Dainippon_Sumitomo_Pharma
|
| gptkbp:eliminationHalfLife |
18 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:firstApproval |
2010
|
| https://www.w3.org/2000/01/rdf-schema#label |
lurasidone
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
B3 (Australia) |
| gptkbp:proteinBinding |
99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
agitation somnolence parkinsonism akathisia |
| gptkbp:synonym |
SM-13496
|
| gptkbp:usedFor |
schizophrenia
bipolar depression |
| gptkbp:bfsParent |
gptkb:Latuda
gptkb:N05AX gptkb:5-HT2C_receptor |
| gptkbp:bfsLayer |
7
|